N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: Studies on the metformin-trimethoprim interaction

European Journal of Clinical Pharmacology

Volumn 71, Issue 1, 2015, Pages 85-94

  Müller, Fabian ^a   Pontones, Constanza A ^a   Renner, Bertold ^a   Mieth, Maren ^a   Hoier, Eva ^a   Auge, Daniel ^a   Maas, Renke ^a   Zolk, Oliver ^b   Fromm, Martin F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

MATE1; Multidrug and toxin extrusion protein; N1 methylnicotinamide; NMN; OCT2; OGTT; Oral glucose tolerance test; Organic cation transporter 2

Indexed keywords

1 METHYLNICOTINAMIDE; GLUCOSE; MATE2 K PROTEIN; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; ORGANIC CATION TRANSPORTER 2; PROTEIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CREATININE; GLUCOSE BLOOD LEVEL; N(1)-METHYLNICOTINAMIDE; NICOTINAMIDE; ORGANIC CATION TRANSPORTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; ELIMINATION RATE CONSTANT; EMBRYO; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; DRUG INTERACTION; HEK293 CELL LINE; KIDNEY; METABOLISM; URINE; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; CREATININE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; METFORMIN; NIACINAMIDE; ORGANIC CATION TRANSPORT PROTEINS; TRIMETHOPRIM; YOUNG ADULT;

EID: 84922084054     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1770-2     Document Type: Article

References (34)

1. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236
2. König J, Müller F, Fromm MF (2013) Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 65:944-966
3. Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM (2013) Renal transporters in drug development. Annu Rev Pharmacol Toxicol 53:503-529
4. Lepist EI, Ray AS (2012) Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol 8:433-448
5. Nies AT, Koepsell H, Damme K, Schwab M (2011) Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 201:105-167
6. Motohashi H, Inui K (2013) Multidrug and toxin extrusion family SLC47: physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Mol Aspects Med 34:661-668
7. Koepsell H (2013) Polyspecific organic cation transporters and their biomedical relevance in kidney. Curr Opin Nephrol Hypertens 22:533-538
8. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F (1987) Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23:545-551
9. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, Sugiyama Y (2011) Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89:837-844
10. Grün B, Kiessling MK, Burhenne J, Riedel KD, Weiss J, Rauch G, Haefeli WE, Czock D (2013) Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. Br J Clin Pharmacol 76:787-796
11. European Medicines Agency (2012) Guideline on the investigation of drug interactions. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2012/07/news-detail-001561.jsp&mid=WC0b01ac058004d5c1
12. FDA (2012) Guidance for industry: drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations (Draft Guidance). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm
13. Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L (2013) Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther 94:52-63
14. Ito S, Kusuhara H, Kumagai Y, Moriyama Y, Inoue K, Kondo T, Nakayama H, Horita S, Tanabe K, Yuasa H, Sugiyama Y (2012) N-Methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin Pharmacol Ther 92:635-641
15. Bi HC, Pan YZ, Qiu JX, Krausz KW, Li F, Johnson CH, Jiang CT, Gonzalez FJ, Yu AM (2014) N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis 35:2264-2272
16. Kitamura S, Nitta K, Tayama Y, Tanoue C, Sugihara K, Inoue T, Horie T, Ohta S (2008) Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:1202-1205
17. 1-methylnicotinamide in humans. J Pharmacokinet Biopharm 19:553-574
18. Müller F, König J, Hoier E, Mandery K, Fromm MF (2013) Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol 86:808-815
19. Schwabedissen HE M, Verstuyft C, Kroemer HK, Becquemont L, Kim RB (2010) Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2, and single nucleotide polymorphisms. Am J Physiol Renal Physiol 298:F997-F1005
20. Lepist EI, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, Murray BP, Bannister R, Cihlar T, Huang Y, Ray AS (2014) Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int 86:350-357
21. Müller F, König J, Glaeser H, Schmidt I, Zolk O, Fromm MF, Maas R (2011) Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother 55:3091-3098
22. Mandery K, Balk B, Bujok K, Schmidt I, Fromm MF, Glaeser H (2012) Inhibition of hepatic uptake transporters by flavonoids. Eur J Pharm Sci 46:79-85
23. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422-1431
24. Gyr N, Berger W, Fridrich R, Denes A, Stalder GA (1971) Effect of dimethylbiguanide on stomach emptying and on oral glucose tolerance. Schweiz Med Wochenschr 101:1876-1879
25. Kim A, Chung I, Yoon SH, Yu KS, Lim KS, Cho JY, Lee H, Jang IJ, Chung JY (2014) Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos 42:1174-1179
26. Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, Park MS, Chung JY (2011) Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther 89:416-421
27. Khan GA, Lindberg R, Grabic R, Fick J (2012) The development and application of a system for simultaneously determining antiinfectives and nasal decongestants using on-line solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 66:24-32
28. Mistri HN, Jangid AG, Shrivastav PS (2007) Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasma. J Pharm Biomed Anal 45:97-106
29. Zhang W, Han F, Zhao H, Lin ZJ, Huang QM, Weng N (2012) Determination of metformin in rat plasma by HILIC-MS/MS combined with Tecan automation and direct injection. Biomed Chromatogr 26:1163-1169
30. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55:170-171
31. Shim CK, Sawada Y, Iga T, Hanano M (1983) Effect of experimental acute renal failure on intrinsic renal tubular secretory clearance of organic cations in rats. J Pharmacobiodyn 6:787-789
32. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drugdrug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412
33. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302:510-515
34. Fromm MF (2012) Prediction of transporter-mediated drug-drug interactions using endogenous compounds. Clin Pharmacol Ther 92:546-548